PharmAbcine (South Korea) a development-stage biopharma company focused on the development of monoclonal antibodies for cancer and inflammatory disease, closed a $6M Series A financing. Participants include OrbiMed, Novartis Venture Fund, Green Cross, Tong Yang Venture Capital and Saehan Venture Fund.